AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2021

Feb 23, 2021

32254_dirs_2021-02-23_5f867c70-d729-43d1-9225-13008932658d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-02-21

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-21	Common Stock	M	13717.00	$0.00	Acquired	96579.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-21	Restricted Stock Units	$0.00	M	13717.00	Disposed		Common Stock (13717.00)	Direct

Footnotes

F1: Includes 878 shares acquired on July 31, 2020 and 3,541 shares acquired on January 29, 2021 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: The restricted stock units vest in three ratable annual installments beginning February 21, 2020.